GWLL GOLDENWELL BIOTECH, INC.
Food and Kindred Products · OTC · SEC CIK 1800373 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-94.1%
TTM net income YoY-12.4%
TTM EPS YoY—
Revenue 3-yr CAGR-79.9%
Net income 3-yr CAGR—
Margins
Gross margin50.4%
Operating margin-88,556.1%
Net margin-94,542.4%
FCF margin—
EBITDA margin—
Returns
ROE-710.0%
ROA-58.1%
ROIC (approx.)-125.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets121.1%
Debt / equity—
Current ratio—
Interest coverage-14.65x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $55 | $139 | $1,836 | $47,800 | $15,967 |
| Cost of revenue | $43 | $75 | $1,170 | $22,614 | $7,579 |
| Gross profit | $12 | $64 | $666 | $25,186 | $8,388 |
| SG&A expense | $113,338 | $123,162 | $116,492 | $1.01M | $126,655 |
| Operating income | -$113,326 | -$123,098 | -$115,826 | -$985,105 | -$118,267 |
| Interest expense | $8,400 | $8,400 | $1,535 | — | $0 |
| Pretax income | — | -$131,498 | -$117,361 | — | -$118,267 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$296,471 | -$131,498 | -$117,361 | -$985,097 | -$116,981 |
| EPS (basic) | — | — | — | — | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 99.00M | 99.00M | 99.00M | — | 91.32M |
| Banking | |||||
| Noninterest expense | — | $8,400 | $1,535 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $26,775 | $49,404 | $53,231 | $45,996 | $213,556 |
| Receivables | — | — | — | $0 | $0 |
| Inventory | $174,745 | $174,788 | $174,863 | $176,058 | $198,671 |
| Total assets | $36,120 | $224,192 | $228,094 | $248,400 | $460,979 |
| Current liabilities | $101,860 | $1,860 | — | — | $159,266 |
| Long-term debt | — | $173,985 | $46,335 | — | — |
| Total debt | — | $173,985 | $46,335 | — | — |
| Total liabilities | $424,833 | $271,433 | $143,837 | $46,782 | $159,266 |
| Shareholders' equity | -$343,713 | -$47,241 | $84,257 | $201,618 | $301,713 |
| Net debt | — | $124,581 | -$6,896 | — | — |
| Shares outstanding | 99.00M | 99.00M | 99.00M | 99.00M | 91.50M |
| Cash flow statement | |||||
| Operating cash flow | -$22,629 | -$123,077 | -$113,153 | -$1.07M | -$205,138 |
| Financing cash flow | $0 | $119,250 | $120,388 | $905,000 | $170,125 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.